Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - Vaccine, 2016 - Elsevier
Background Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated
diarrhoea and colitis and the most common pathogen of health care-associated infections. In …
被引用次数：101 相关文章

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - 2016 - cabidigitallibrary.org
Background: Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated
diarrhoea and colitis and the most common pathogen of health care-associated infections. In …

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - Vaccine, 2016 - europepmc.org
Background Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated
diarrhoea and colitis and the most common pathogen of health care-associated infections. In …

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - Vaccine, 2016 - infona.pl
Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated diarrhoea
and colitis and the most common pathogen of health care-associated infections. In the US …

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

N Bézay, A Ayad, K Dubischar, C Firbas… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated
diarrhoea and colitis and the most common pathogen of health care-associated infections. In …

[引用][C] Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - Vaccine, 2016 - Elsevier Limited

[引用][C] Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

N Bézay, A Ayad, K Dubischar, C Firbas, R Hochreiter… - 2016